Category Archives: News

Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of ALS under the Notice of Compliance with Conditions (NOC/c) policy

21/02/2022 – AB Science today announces that Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of amyotrophic lateral sclerosis (ALS) under the Notice of Compliance with Conditions (NOC/c) policy

Clarification following the February 11, 2022 public hearing of the Enforcement Committee of the French Market Regulator (AMF)

12/02/2022 – AB Science wishes to provide clarifications following press articles published after the public hearing of the Enforcement Committee of the French market regulator (AMF) on Friday, February 11, 2022

AB Science to present on its Amyotrophic Lateral Sclerosis (ALS) development program at the 2022 ALS Drug Development Summit

07/02/2022 – AB Science will deliver a presentation on the Amyotrophic Lateral Sclerosis (ALS) masitinib development program at the 2022 ALS Drug Development Summit

AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the Swedish Medical Products Agency

02/02/2022 – AB Science today announces that it has been authorized by the Swedish Medical Products Agency, to initiate a Phase III study (AB20009) evaluating masitinib in patients with Primary Progressive Multiple Sclerosis (PPMS) or non-active Secondary Progressive Multiple Sclerosis (nSPMS)

AB Science granted authorization to initiate Phase II study in patients with severe mast cell activation syndrome by the French Health Authority (ANSM)

19/01/2022 – AB Science today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase II study (AB20006) in patients with severe mast cell activation syndrome

AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the French Health Authority (ANSM)

03/01/2022 – AB Science today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase III study (AB20009) evaluating masitinib in patients with Primary Progressive Multiple Sclerosis (PPMS) or non-active Secondary Progressive Multiple Sclerosis (nSPMS)

AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus

29/11/2021 – AB Science today announced that the first patient has been dosed in the phase 2 trial evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19

AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia

22/11/2021 – AB Science today announces that its Phase I/II study (AB18001) evaluating AB8939 in patients with refractory and relapsed AML and refractory myelodysplastic syndrome (MDS) has received Investigational New Drug (IND) approval by the U.S. Food and Drug Administration (FDA)

AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS

18/11/2021 – AB Science today announced that it has received authorization from the United States Food and Drug Administration (FDA) to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with amyotrophic lateral sclerosis (ALS)

AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)

18/10/2021 – AB Science announced that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase I/II study (AB18001) evaluating AB8939 in patients with refractory and relapsed AML